Transcript
Transcript
Transcript
I’m very interesting set of people here with me to talk about AI. Krishna Mehra at Elevation, Supreet Deshpande, the cofounder of Cynthia Olab, Deepak Tantra of Adopt AI and Abhishek Combat, the founder of Goodyera Supriti. Wanna start by asking you, tell us a little bit about the problem that you’re hoping to solve in an AI world. And of course, the focus for you is power. So that’s in two labs. What we do is we completely kind of reimagine what pharma go to market model looks like over the last two decades. It’s predominantly. In human LED, right? And in some sense, no technology can unlock things that weren’t possible. So one example is can you have an AI engaged with physicians who are the end customers for pharma and have that expert sort of on 24/7? Now, of course, a lot of things around that come with compliance regulations, what the FDA thinks about it, but I think that also makes it very interesting. So it’s a massive space, you know, often unknown. Has been on what can I do to drug discovery, What can I do in terms of breakthroughs for, you know, mega complex problems, healthcare problems, but you’re actually addressing the other side of the spectrum. Absolutely. And I think I think that’s a good point because you know, oftentimes when we talk about pharma and I happening, we talk about drug discovery, which is extremely upstream. But if you think about spend, right, you do a map of where all the spend happens. A large part of it is commercial and today almost half of that, I think it’s close to 300 billion plus in spend. A significant portion of that is just services, right, like the Accenture, Deloitte’s use of the world and what’s happened is over the last two decades because of either call it lack of technology or just how the process where there were too many processes that were added on, right, right. And it sort of layered on. And I think now it’s an incredible time to just completely rethink that go to market model and a bunch of other interesting aliens to that, right. So if you think about GLP ones of the world now you’re talking about a drug class where your customer base is pretty much. Physician, yes. So you’ll go to market model cannot we’ll have 1000 reps, right, because the economic model on that will never make sense. So I think you guys going to play an incredible role there to rethink what that go to market model for pharma would look like. OK, so your base of course here is in the Valley, but you do have a foot in India as well. Yeah. So we we in fact have a couple of juniors and we are kind of growing that team a lot. A lot of that is sort of either. Seen at work where they were engineers building there. But you know, the way we are seeing is in fact a lot of our kind of actual product built and even we’re deployed engineers. We have educated folks in India that are helping us build. So, yeah, so in fact, we recently got 5, five of them here. They’re spending some time with us. We have a nice apartment here in the Bay Area that kind of hosts our folks from India that come here. No, I think we’re really excited about that model.
